{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:33:17Z","timestamp":1786120397405,"version":"build-2736575974"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/cco.0b013e32834d1b22","type":"journal-article","created":{"date-parts":[[2011,10,12]],"date-time":"2011-10-12T04:28:40Z","timestamp":1318393720000},"page":"609-616","source":"Crossref","is-referenced-by-count":27,"title":["Janus kinase inhibitors"],"prefix":"10.1097","volume":"23","author":[{"given":"Brady L.","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Crispino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison R.","family":"Moliterno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210128","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"R2-9-20210128","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"R4-9-20210128","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"R5-9-20210128","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"R6-9-20210128","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1001\/jama.2010.853","article-title":"Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation.","volume":"303","author":"Stein","year":"2010","journal-title":"JAMA"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000101707","article-title":"Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy.","volume":"74","author":"Macdonald","year":"2007","journal-title":"Pathobiology"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders.","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2008-03-077966","article-title":"Myeloproliferative disorders.","volume":"112","author":"Levine","year":"2008","journal-title":"Blood"},{"key":"R12-9-20210128","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"key":"R13-9-20210128","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1182\/blood-2007-06-095703","article-title":"Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders.","volume":"111","author":"Pardanani","year":"2008","journal-title":"Blood"},{"key":"R14-9-20210128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.exphem.2010.09.008","article-title":"Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.","volume":"39","author":"Stein","year":"2011","journal-title":"Exp Hematol"},{"key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"key":"R16-9-20210128","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617VF mutation in patients with polycythemia vera or essential thrombocythemia.","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden.","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"R18-9-20210128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.leukres.2010.06.017","article-title":"JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy.","volume":"35","author":"Silver","year":"2011","journal-title":"Leuk Res"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2141.2009.07804.x","article-title":"Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients.","volume":"146","author":"Alvarez-Larran","year":"2009","journal-title":"Br J Haematol"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"R22-9-20210128","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"R23-9-20210128","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"R24-9-20210128","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"key":"R25-9-20210128","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The myelofibrosis symptom assessment form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk Res"},{"issue":"21","key":"R26-9-20210128","first-page":"4095","article-title":"The myeloproliferative neoplasm symptom assessment form (MPN-SAF): an international prospective validation trial in 402 patients.","volume":"116","author":"Scherber","year":"2010","journal-title":"Blood ASH Annual Meeting Abstracts"},{"key":"R27-9-20210128","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"key":"R28-9-20210128","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"R29-9-20210128","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ajh.21574","article-title":"Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis: prognostic relevance is independent of IPSS or karyotype.","volume":"85","author":"Tefferi","year":"2010","journal-title":"Am J Hematol"},{"key":"R30-9-20210128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2010.031831","article-title":"Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.","volume":"96","author":"Elena","year":"2011","journal-title":"Haematologica"},{"key":"R31-9-20210128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","article-title":"The haematocrit and platelet target in polycythemia vera.","volume":"136","author":"Di Nisio","year":"2007","journal-title":"Br J Haematol"},{"key":"R32-9-20210128","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00277-010-1154-3","article-title":"Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study.","volume":"90","author":"Palandri","year":"2011","journal-title":"Ann Hematol"},{"key":"R33-9-20210128","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"R34-9-20210128","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"R35-9-20210128","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera.","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"R36-9-20210128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R37-9-20210128","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","article-title":"Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation.","volume":"138","author":"Gangat","year":"2007","journal-title":"Br J Haematol"},{"key":"R38-9-20210128","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"key":"R39-9-20210128","first-page":"457","article-title":"Survival and risk of leukemic transformation in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study on 1104 patients.","volume":"116","author":"Barbui","year":"2010","journal-title":"Blood ASH Annual Meeting Abstracts"},{"key":"R40-9-20210128","first-page":"4104","article-title":"DIPSS-Plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates karyotype, platelet count and transfusion status abstract 4104.","volume":"116","author":"Gangat","year":"2010","journal-title":"Blood ASH Annual Meeting Abstracts"},{"key":"R42-9-20210128","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK12 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"},{"key":"R43-9-20210128","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1182\/blood-2007-04-083402","article-title":"Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.","volume":"111","author":"Hexner","year":"2008","journal-title":"Blood"},{"key":"R44-9-20210128","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.","volume":"13","author":"Wernig","year":"2008","journal-title":"Cancer Cell"},{"key":"R45-9-20210128","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","article-title":"CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.","volume":"115","author":"Tyner","year":"2010","journal-title":"Blood"},{"key":"R46-9-20210128","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2009.50","article-title":"CYT387, a selective JAK1JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.","volume":"23","author":"Pardanani","year":"2009","journal-title":"Leukemia"},{"key":"R47-9-20210128","first-page":"3905","article-title":"Phase I dose-escalation trial of SB1518, a novel JAK2FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemiapolycythemia vera myelofibrosis.","volume":"114","author":"Verstovsek","year":"2009","journal-title":"Blood ASH Annual Meeting Abstracts"},{"issue":"Suppl","key":"R48-9-20210128","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1200\/jco.2011.29.15_suppl.6500","article-title":"Results of COMFORT-1, a randomized double-blind phase III trial of INCB18424 versus placebo for patients with myelofibrosis.","volume":"29","author":"Verstovsek","year":"2011","journal-title":"J Clin Oncol"},{"key":"R50-9-20210128","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","article-title":"Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or postpolycythemia veraessential thrombocythemia myelofibrosis.","volume":"115","author":"Santos","year":"2010","journal-title":"Blood"},{"key":"R51-9-20210128","first-page":"754","article-title":"A multicenter, open label phase III study of CEP701 (lestaurtinib) in adults with myelofibrosis: a report on phase I A study of the Myeloproliferative Disorders Research Consortium (MPD-RC).","volume":"114","author":"Hexner","year":"2009","journal-title":"Blood ASH Annual Meeting Abstracts"},{"key":"R52-9-20210128","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"key":"R55-9-20210128","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"R56-9-20210128","first-page":"313","article-title":"Durable responses with the JAK1JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU).","volume":"116","author":"Verstovsek","year":"2010","journal-title":"Blood ASH Annual Meeting Abstracts"},{"key":"R57-9-20210128","first-page":"753","article-title":"An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients.","volume":"114","author":"Moliterno","year":"2009","journal-title":"Blood ASH Annual Meeting Abstracts"},{"key":"R58-9-20210128","first-page":"4109","article-title":"A phase-2 trial of low-dose pomalidomide in myelofibrosis with anemia.","volume":"116","author":"Begna","year":"2010","journal-title":"Blood ASH Annual Meeting Abstracts"},{"key":"R59-9-20210128","first-page":"314","article-title":"A phase 12 study of RAD001, a mTOR inhibitor, in patients with myelofibrosis: final results.","volume":"116","author":"Vannucchi","year":"2010","journal-title":"Blood ASH Annual Meeting Abstracts"},{"key":"R60-9-20210128","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"R61-9-20210128","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"R62-9-20210128","first-page":"4103","article-title":"Efficacy and safety of Peg-interferon-alpha2a in myelofibrosis: a study of the FIM and GEM French Cooperative Groups.","volume":"116","author":"Ianotto","year":"2010","journal-title":"Blood ASH Annual Meeting Abstracts"},{"key":"R63-9-20210128","first-page":"461","article-title":"High rates of molecular response after long-term follow-up of patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV) treated with pegylated interferon-alfa-2A (PEG-IFN-alpha-2A; PEGASYS).","volume":"116","author":"Quintas-Cardama","year":"2010","journal-title":"Blood ASH Annual Meeting Abstracts"},{"key":"R64-9-20210128","first-page":"630","article-title":"A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post essential thrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis.","volume":"116","author":"DeAngelo","year":"2010","journal-title":"Blood ASH Annual Meeting Abstracts"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e32834d1b22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:32:23Z","timestamp":1786048343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-201111000-00009"}},"subtitle":["an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms"],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32834d1b22","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}